Wegovy postpartum: what you can and can't do after having a baby

The myth that needs correcting first: 'I'll just wait six weeks and then start'

The idea that the standard six-week postnatal check clears you for any weight-loss medicine is widespread and understandable. It does not apply to Wegovy. The six-week appointment covers your general recovery and contraception, but it is not a green light for GLP-1 treatment, and no legitimate prescriber would treat it as one.

The reason is straightforward: if you are breastfeeding, Wegovy is simply not appropriate. Semaglutide has not been studied in breastfeeding women, and the possibility that it passes into breast milk cannot be ruled out. UK guidance is unambiguous here. The NHS patient information on semaglutide states clearly that it is not recommended for women who are breastfeeding. That is not a precautionary hedge; it reflects a genuine evidence gap that no prescriber should ask you to overlook.

What can change the picture is whether you have stopped breastfeeding entirely, how much time has passed, and what your overall health looks like. That is a clinical conversation, not something a webpage can resolve.

What UK guidance actually says about postpartum eligibility for Wegovy

Wegovy holds a UK licence for weight management in adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related health condition, such as high blood pressure, high cholesterol, or type 2 diabetes. Those numbers apply at any adult life stage, including after childbirth, provided the clinical picture supports treatment.

In practice, a prescriber assessing a postpartum patient who is not breastfeeding will look at several things beyond BMI: how recently you gave birth, whether your weight has had any chance to settle naturally, current medications (some postnatal medicines interact with GLP-1 drugs), mental health, thyroid function if relevant, and contraception. The MHRA advises using reliable contraception while on semaglutide, and for any woman of childbearing age this forms part of the assessment. You can read more about how Wegovy works and what it is licensed for in the UK to give yourself a fuller picture before any consultation.

NICE's appraisal of semaglutide (TA875) also specifies that it should be used within a structured programme that includes dietary and physical activity support, worth knowing because the demands of new parenthood may affect what kind of lifestyle programme is realistic. A prescriber will factor that in too.

The contraception and conception questions that often catch people out

Two questions our prescribers hear regularly from postpartum patients: does Wegovy affect contraception, and when is it safe to try for another pregnancy?

On contraception: NHS England guidance notes that for tirzepatide specifically there is evidence that oral contraceptive absorption can be affected, making a non-oral backup method advisable during the early weeks of treatment. For semaglutide (Wegovy), the NHS does not flag the same pill-absorption concern, but contraception is still strongly recommended throughout treatment for anyone who could become pregnant. An unplanned pregnancy while on Wegovy would require stopping the medicine immediately.

On trying to conceive: the MHRA is clear that semaglutide should not be used during pregnancy, and guidance recommends stopping it and allowing a wash-out period before attempting conception. The exact timing is something to agree with your prescriber; it depends on your dose and how long you have been taking it. If you are curious about what happens to weight after stopping, our page on weight changes after Wegovy explains what the evidence shows. Anyone actively trying for a baby should discuss the timing explicitly before starting treatment.

Getting assessed: what a legitimate postpartum consultation looks like

If you are not breastfeeding, your postnatal recovery is well established, and you are using reliable contraception, you may be a reasonable candidate for a clinical assessment. That does not mean automatic approval, it means a prescriber will look at your full history and decide whether the benefits outweigh any risks for you specifically.

Some patients come to us having read accounts from people who have been through Wegovy treatment and want to explore whether those findings apply to their own situation, and many find it useful to also review the positive effects that Wegovy can produce so they understand what successful treatment can look like in practice. That is the right instinct: read, ask questions, then get an individual assessment. Rushing into treatment without that step is where things go wrong, and the postpartum period (with its hormonal shifts, sleep deprivation, and changing appetite patterns) makes a thorough review more important, not less.

Wegovy is a prescription-only medicine that must be dispensed by a registered pharmacy following assessment by a qualified prescriber. At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber. Our pharmacy's registration is verifiable on the GPhC register (registration 9012878). If you are approved and order by midday, your treatment is dispatched the same day and delivered free the next working day by DPD, tracked, in plain packaging, ready to go before the afternoon school run.

Thinking about the broader landscape of weight-loss treatment options first can help you arrive at a consultation with the right questions already in mind, and it is also worth understanding whether weight gain on Wegovy is possible so you have realistic expectations before you begin.